Neuroendocrine abnormalities in Parkinson's disease

Eduardo De Pablo-Fernández, David P Breen, Pierre M Bouloux, Roger A Barker, Thomas Foltynie, Thomas T Warner

Research output: Contribution to journalReview articlepeer-review

Abstract

Neuroendocrine abnormalities are common in Parkinson's disease (PD) and include disruption of melatonin secretion, disturbances of glucose, insulin resistance and bone metabolism, and body weight changes. They have been associated with multiple non-motor symptoms in PD and have important clinical consequences, including therapeutics. Some of the underlying mechanisms have been implicated in the pathogenesis of PD and represent promising targets for the development of disease biomarkers and neuroprotective therapies. In this systems-based review, we describe clinically relevant neuroendocrine abnormalities in Parkinson's disease to highlight their role in overall phenotype. We discuss pathophysiological mechanisms, clinical implications, and pharmacological and non-pharmacological interventions based on the current evidence. We also review recent advances in the field, focusing on the potential targets for development of neuroprotective drugs in Parkinson's disease and suggest future areas for research.

Original languageEnglish
Pages (from-to)176-185
Number of pages10
JournalJournal of Neurology, Neurosurgery & Psychiatry
Volume88
Issue number2
Early online date31 Oct 2016
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Blood Glucose/metabolism
  • Body Weight/physiology
  • Bone Density/physiology
  • Glucose Intolerance/complications
  • Humans
  • Insulin Resistance/physiology
  • Parkinson Disease/complications

Fingerprint Dive into the research topics of 'Neuroendocrine abnormalities in Parkinson's disease'. Together they form a unique fingerprint.

Cite this